Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient

ABSTRACT We describe the acquisition of flucytosine, azole, and caspofungin resistance in sequential Candida glabrata bloodstream isolates collected from a bone marrow transplant patient with clinical failure. Point mutations in C. glabrata FUR1 (CgFUR1) and CgFKS2 and overexpression of CgCDR1 and CgCDR2 were observed in resistant isolates.

[1]  J. Cleary,et al.  Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.

[2]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  B. Dujon,et al.  Uneven Distribution of Mating Types among Genotypes of Candida glabrata Isolates from Clinical Samples , 2009, Eukaryotic Cell.

[4]  T. Patterson,et al.  Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection , 2008, Antimicrobial Agents and Chemotherapy.

[5]  M. Ghannoum,et al.  Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints , 2008, Journal of Clinical Microbiology.

[6]  D. Kontoyiannis,et al.  The changing epidemiology of invasive candidiasis , 2008, Cancer.

[7]  J. Cleary,et al.  Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment , 2008, Antimicrobial Agents and Chemotherapy.

[8]  M. Pfaller,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing , 2007, Journal of Clinical Microbiology.

[9]  S. Suh,et al.  Changes in Karyotype and Azole Susceptibility of Sequential Bloodstream Isolates from Patients with Candida glabrata Candidemia , 2007, Journal of Clinical Microbiology.

[10]  D. Perlin.  Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  J. Meis,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing , 2007, Journal of Clinical Microbiology.

[12]  J. Villard,et al.  Molecular Mechanism of Flucytosine Resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 Genes to 5-Fluorouracil and Fluconazole Cross-Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[13]  S. Katiyar,et al.  Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility , 2006, Antimicrobial Agents and Chemotherapy.

[14]  M. Arendrup,et al.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Villard,et al.  Inactivation of the FCY2 Gene Encoding Purine-Cytosine Permease Promotes Cross-Resistance to Flucytosine and Fluconazole in Candida lusitaniae , 2005, Antimicrobial Agents and Chemotherapy.

[16]  G. Fadda,et al.  Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance , 2005, Antimicrobial Agents and Chemotherapy.

[17]  M. Pfaller,et al.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. , 2004, Diagnostic microbiology and infectious disease.

[18]  M. Ghannoum,et al.  Mechanisms of fungal resistance: an overview. , 2002, Drugs.

[19]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.